MX2018013943A - Metodo de tratamiento de hiperglucemia. - Google Patents
Metodo de tratamiento de hiperglucemia.Info
- Publication number
- MX2018013943A MX2018013943A MX2018013943A MX2018013943A MX2018013943A MX 2018013943 A MX2018013943 A MX 2018013943A MX 2018013943 A MX2018013943 A MX 2018013943A MX 2018013943 A MX2018013943 A MX 2018013943A MX 2018013943 A MX2018013943 A MX 2018013943A
- Authority
- MX
- Mexico
- Prior art keywords
- disorders related
- hyperglycemia
- conditions
- diabetes
- treating hyperglycemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Abstract
En el presente documento se describen metodos para tratar afecciones y/o trastornos relacionados con la hiperglucemia. Dichas afecciones y/o trastornos relacionados con la hiperglucemia incluyen, pero no se limitan a, diabetes mellitus tipo I, tipo II, diabetes gestacional, otras formas de diabetes y trastornos relacionados con la misma. En particular, la presente invención se refiere a metodos de uso de (R)-(+)-verapamilo o una sal farmaceuticamente aceptable del mismo en el tratamiento de afecciones y/o trastornos relacionados con la hiperglucemia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662339131P | 2016-05-20 | 2016-05-20 | |
PCT/CN2017/084746 WO2017198177A1 (en) | 2016-05-20 | 2017-05-17 | Method of treating hyperglycemia |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018013943A true MX2018013943A (es) | 2019-03-28 |
Family
ID=60326464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018013943A MX2018013943A (es) | 2016-05-20 | 2017-05-17 | Metodo de tratamiento de hiperglucemia. |
Country Status (15)
Country | Link |
---|---|
US (2) | US9980935B2 (es) |
EP (1) | EP3413886A4 (es) |
JP (3) | JP6692903B2 (es) |
KR (3) | KR102423967B1 (es) |
CN (2) | CN113384571A (es) |
AU (1) | AU2017267006B2 (es) |
BR (1) | BR112018073688A2 (es) |
CA (2) | CA3003319C (es) |
HK (1) | HK1254471A1 (es) |
IL (1) | IL262994B2 (es) |
MX (1) | MX2018013943A (es) |
RU (2) | RU2739255C2 (es) |
SG (1) | SG11201809899RA (es) |
TW (1) | TWI659738B (es) |
WO (1) | WO2017198177A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113384571A (zh) * | 2016-05-20 | 2021-09-14 | 晟德大药厂股份有限公司 | (r)-(+)-维拉帕米用于治疗高血糖的用途及其药学组合物 |
US10639292B2 (en) | 2018-04-20 | 2020-05-05 | Center Laboratories, Inc. | Method of treating hyperglycemia |
EP3981401A1 (en) * | 2020-10-06 | 2022-04-13 | InSphero AG | Pharmaceutical combination for the treatment and/or prevention of diabetes comprising a calcium channel blocking agent and an incretin mimetic |
CN117241798A (zh) * | 2021-04-29 | 2023-12-15 | 日东制药股份有限公司 | 包括gpr40促进剂以及sglt-2抑制物的医药组成物 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9616549D0 (en) * | 1996-08-06 | 1996-09-25 | Chiroscience Ltd | Therapeutic product and its use |
US20030092765A1 (en) * | 2001-11-15 | 2003-05-15 | John Kelly | Treatment of abnormal increases in gastrointestinal motility with (R)-verapamil |
ES2390231T3 (es) * | 2005-06-03 | 2012-11-07 | Mitsubishi Tanabe Pharma Corporation | Agentes farmacéuticos concomitantes y su uso |
RU2338521C1 (ru) * | 2007-02-28 | 2008-11-20 | Илья Николаевич Медведев | Способ быстрого снижения активности тромбопластиногенерации у лиц с метаболическим синдромом |
CA2755068C (en) * | 2009-03-12 | 2018-11-06 | Nordic Bioscience A/S | Treatment of diabetes and metabolic syndrome |
CN101869708A (zh) * | 2009-04-24 | 2010-10-27 | 北京奥萨医药研究中心有限公司 | 含有钙通道阻滞剂和双胍类降糖药物的药物组合物及其用途 |
WO2010138535A1 (en) * | 2009-05-27 | 2010-12-02 | Bristol-Myers Squibb Company | Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an sglt2 inhibitor and compositions thereof |
TWI410630B (zh) * | 2009-11-10 | 2013-10-01 | Ct Lab Inc | 一種用以治療與食慾素受體1、食慾素受體2、體抑素受體2或多巴胺d2l受體相關之疾病的方法和組合物 |
AU2010319438B2 (en) * | 2009-11-13 | 2015-05-21 | Astrazeneca Uk Limited | Reduced mass metformin formulations |
EP2573088A1 (en) * | 2011-09-26 | 2013-03-27 | Prous Institute for Biomedical Research, S.A. | Pyrano[3,2-c]benzopyran-6(2h)-one derivatives and uses thereof |
US10314851B2 (en) * | 2014-03-17 | 2019-06-11 | Massachusetts Institute Of Technology | Metakaryocidal treatments |
CA2964177A1 (en) * | 2014-10-29 | 2016-05-06 | Center Laboratories, Inc. | Crystal forms of verapamil hydrochloride |
CN113384571A (zh) * | 2016-05-20 | 2021-09-14 | 晟德大药厂股份有限公司 | (r)-(+)-维拉帕米用于治疗高血糖的用途及其药学组合物 |
-
2017
- 2017-05-17 CN CN202110545191.XA patent/CN113384571A/zh active Pending
- 2017-05-17 BR BR112018073688-0A patent/BR112018073688A2/pt active Search and Examination
- 2017-05-17 KR KR1020217031124A patent/KR102423967B1/ko active IP Right Grant
- 2017-05-17 EP EP17798740.1A patent/EP3413886A4/en not_active Withdrawn
- 2017-05-17 WO PCT/CN2017/084746 patent/WO2017198177A1/en active Application Filing
- 2017-05-17 CA CA3003319A patent/CA3003319C/en active Active
- 2017-05-17 CA CA3114057A patent/CA3114057A1/en not_active Abandoned
- 2017-05-17 RU RU2018139578A patent/RU2739255C2/ru active
- 2017-05-17 AU AU2017267006A patent/AU2017267006B2/en active Active
- 2017-05-17 US US15/597,200 patent/US9980935B2/en active Active
- 2017-05-17 CN CN201780003723.9A patent/CN108430467B/zh active Active
- 2017-05-17 SG SG11201809899RA patent/SG11201809899RA/en unknown
- 2017-05-17 KR KR1020207037511A patent/KR20210000757A/ko not_active Application Discontinuation
- 2017-05-17 RU RU2020140694A patent/RU2020140694A/ru not_active Application Discontinuation
- 2017-05-17 MX MX2018013943A patent/MX2018013943A/es unknown
- 2017-05-17 JP JP2018521403A patent/JP6692903B2/ja active Active
- 2017-05-17 TW TW106116239A patent/TWI659738B/zh active
- 2017-05-17 KR KR1020187012063A patent/KR102200664B1/ko active IP Right Grant
-
2018
- 2018-04-20 US US15/957,956 patent/US10278943B2/en active Active
- 2018-10-23 HK HK18113557.8A patent/HK1254471A1/zh unknown
- 2018-11-13 IL IL262994A patent/IL262994B2/en unknown
-
2020
- 2020-02-27 JP JP2020032083A patent/JP2020100651A/ja active Pending
-
2022
- 2022-01-11 JP JP2022002081A patent/JP7266327B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA521430638B1 (ar) | H مركبات بيرميدين-2-يل أمينو-1 lrrk2 بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبية | |
MX2021012547A (es) | Metodos y composiciones para exterminar celulas senescentes y para tratar enfermedades y trastornos asociados con la senectud. | |
WO2015148863A3 (en) | Crispr/cas-related methods and compositions for treating sickle cell disease | |
EP3395353A4 (en) | METHOD OF PREVENTING OR TREATING DIABETIC NEUROPATHY AND RELATED DISORDERS | |
MX2018013943A (es) | Metodo de tratamiento de hiperglucemia. | |
TW201613636A (en) | Methods of treating Alzheimer's Disease | |
PH12017500933A1 (en) | Sublingual administration of riluzole | |
MX2022003128A (es) | Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular. | |
PH12017500934A1 (en) | Sublingual formulation of riluzole | |
WO2015143447A3 (en) | Methods for treating neurological disorders | |
MX2019004804A (es) | Tratamiento para el prurigo nodula. | |
TW201613639A (en) | Methods for treating cardiovascular diseases | |
MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
MX2020003243A (es) | Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada. | |
TW201613569A (en) | Composition consisting of kukoamine A and/or kukoamine B and method of using thereof | |
WO2015142865A3 (en) | Metakaryocidal treatments | |
MX2019000677A (es) | Células miméticas de células b. | |
EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
MX2021000908A (es) | Tratamiento de la tos cronica, la dificultad respiratoria y la disnea. | |
SG10201809673RA (en) | Treatment of androgen deprivation therapy associated symptoms | |
MX2017003892A (es) | Tratamiento del sindrome de rett. | |
MX2019014784A (es) | Tratamiento para la migra?a. | |
MX2016013588A (es) | Complejo de tanato de sitagliptina. | |
WO2016182812A8 (en) | Activation of neuronal store-operated calcium entry pathway for the treatment of alzheimer's disease | |
NZ747201A (en) | (+)-azasetron for use in the treatment of ear disorders |